The biosimilar will be available in both subcutaneous and intravenous formulations and has nearly all the same indications as ...

Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, ...

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.

Jersey City, New Jersey Saturday, February 1, 2025, 16:00 Hrs [IST] ...

The U.S. Food and Drug Administration (FDA) has approved Celltrion’s AVTOZMA (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and subcutaneous (SC) formulation as a biosimilar to ACTEMRA.

The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.

JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, ...

The clinical results demonstrated that AVTOZMA and its reference tocilizumab are highly similar and have ... The IV infusion is provided as 80 mg/4 mL (20 mg/mL), 200 mg/10 mL (20 mg/mL), 400 mg/20 mL ...

On day 2, tocilizumab was administered ... including intramuscular epinephrine (0.5 mg) and intravenous dopamine (200 mg in 30 mL 0.9% NaCl, administered at 5 mL/h via micropump) to support blood ...